Jazz Pharmaceuticals, Inc.
JAZZ
Key stats
- Open
- 248.96
- Day high
- 249.99
- Day low
- 239.60
- Previous close
- 248.24
- Volume
- 584.4K
- VWAP
- 242.62
- 52-week high
- 266.38
- 52-week low
- 136.27
- Market cap
- 15.93B
- Shares out
- 64.19M
- Employees
- 2,890
- Listed
- 2007
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
PHARMACEUTICAL PREPARATIONS · DUBLIN · jazzpharmaceuticals.com
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 743
- Put open interest
- 564
- Put/call
- 0.76
- At-the-money IV
- 33.9%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 200 put | 0.75 | Nov 3, 2:47 PM | 2.0K | 466 | 83.4% |
| 210 call | 23.52 | Nov 3, 2:46 PM | 22 | 30 | 55.6% |
| 230 call | 13.50 | Nov 12, 2:44 PM | 10 | 253 | 34.0% |
| 250 call | 2.55 | Nov 10, 3:34 PM | 7 | 49 | 39.8% |
| 230 put | 1.03 | Nov 11, 9:45 AM | 3 | 15 | 31.7% |
| 260 call | 0.45 | Nov 5, 2:29 PM | 2 | 41 | 42.7% |
Quarterly results
Massive · Nov 2, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $1.24B | $1.21B | $1.07B | $1.20B |
| Gross profit | $1.13B | $1.09B | $934.80M | $1.04B |
| Operating income | −$413.40M | $248.20M | $213.80M | $254.53M |
| Net income | −$483.40M | $192.80M | $293.10M | $203.45M |
| Diluted EPS | -7.48 | 2.78 | 4.43 | 3.38 |
| Operating cash flow | $506.10M | $415.70M | $408.20M | $362.52M |
| Assets | $12.00B | $11.08B | $11.86B | $11.66B |
| Liabilities | $7.81B | $6.28B | $7.33B | $7.34B |
| Equity | $4.19B | $4.80B | $4.53B | $4.32B |
Technicals
Massive · Nov 12, 2026- 50-day average229.25
- 200-day average219.64
- RSI (14 days)60.0
Short interest
Massive · Oct 30, 2026- Oct 30, 20265.80M shares · 7.7 days to cover
- Oct 15, 20265.86M shares · 6.9 days to cover
- Sep 30, 20265.48M shares · 6.5 days to cover
- Sep 15, 20264.68M shares · 7.2 days to cover
Related companies
MassiveNews coverage
No stories about Jazz Pharmaceuticals, Inc. right now.